WuXi Biologics Signs Antibody Development Deal with Earendil Labs

MT Newswires Live03-13

WuXi Biologics (Cayman) (HKG:2269) said it entered a collaboration with Earendil Labs to support the development and manufacturing of multiple bispecific and multispecific antibodies and antibody-drug conjugate candidates, according to a Thursday press release.

Under the agreement, WuXi Biologics will provide end-to-end biologics development and manufacturing services, including cell line development, process and bioassay development, drug product formulation, and GMP manufacturing.

The programs are part of Earendil Labs' pipeline targeting autoimmune diseases, cancer, and other conditions.

WuXi Biologics said the collaboration aims to accelerate development timelines, improve manufacturing execution, and support global clinical advancement of the candidates.

Earendil Labs is an artificial intelligence-driven biotech company focused on developing next-generation biologics for autoimmune diseases, cancer, and other conditions, the statement said.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment